ArticleJCO precision oncology2020
Clinical Relevance of an Amplicon-Based Liquid Biopsy for Detecting
Article in JCO precision oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy of liquid biopsy for genetic mutations determination in non-small cell lung cancer: a systematic review on literatures.BMC cancer · 2025Pooled it
- Association of anaplastic lymphoma kinase variants and alterations with ensartinib response duration in non-small cell lung cancer.Thoracic cancer · 2021Trial
- Case Report:Frontiers in oncology · 2026Article
- Advances in Liquid Biopsy for Precision Oncology: Applications, Challenges, and Future Directions in Clinical Laboratories.OncoTargets and therapy · 2026Review
- Review
- Implementation of an ISO 15189 accredited next generation sequencing service for cell-free total nucleic acid (cfTNA) analysis to facilitate driver mutation reporting in blood: the experience of a clinical diagnostic laboratory.Journal of clinical pathology · 2025Article
- Review
- Liquid Biopsy in Solid Tumours: An Overview.Cytopathology : official journal of the British Society for Clinical Cytology · 2025Review
- Paving the way for ctDNA-guided trials in lung cancer: insights from the LIBELULE study.Translational lung cancer research · 2025Article
- New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients.NPJ precision oncology · 2024Article
- Real-World Outcomes of Crizotinib in ROS1-Rearranged Advanced Non-Small-Cell Lung Cancer.Cancers · 2024Article
- Fluctuation of Acquired Resistance Mutations and Re-Challenge with EGFR TKI in Metastatic NSCLC: A Case Report.Current oncology (Toronto, Ont.) · 2023Article
- Detecting ALK, ROS1, and RET fusions and the METΔex14 splicing variant in liquid biopsies of non-small-cell lung cancer patients using RNA-based techniques.Molecular oncology · 2023Article
- A narrative review of methods for the identification ofTranslational lung cancer research · 2023Review
- DNAfusion: an R/Bioconductor package for increased sensitivity of detecting gene fusions in liquid biopsies.BMC bioinformatics · 2023Article
- Comparison between Three Different Techniques for the Detection of EGFR Mutations in Liquid Biopsies of Patients with Advanced Stage Lung Adenocarcinoma.International journal of molecular sciences · 2023Article
- Liquid Biopsies in Lung Cancer.Cancers · 2023Review
- The Overview of Perspectives of Clinical Application of Liquid Biopsy in Non-Small-Cell Lung Cancer.Life (Basel, Switzerland) · 2022Review
- Prognostic Value of Circulating Tumor DNA (ctDNA) in Oncogene-Driven NSCLC: Current Knowledge and Future Perspectives.Cancers · 2022Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeLiquid biopsy specimen genomic profiling is integrated in non-small-cell lung cancer (NSCLC) guidelines; however, data on the clinical relevance for PATIENTS AND
methodsPatients with advanced
resultsOf the 128 patients included in the study, 101 were positive for
conclusionNext-generation, targeted, amplicon-based sequencing for liquid biopsy specimen profiling provides clinically relevant detection of
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.